# Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

> clinical trial · VERIFIED · 2026-06-26

Status: RECRUITING · Sponsor: Tyra Biosciences, Inc · Condition: Low-grade NMIBC

- Company: Tyra Biosciences, Inc
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06995677

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.